Effects of clock frequency stability on digital microwave radiometer performance

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/94800/1/rds5731.pd

CSR-Sustainability Monitor 2016 Edition

The report examines how large companies around the world communicate the impact of their non-financial activities through their CSR report (standalone or integrated)

GLA: D Årsrapport 2017

Godt Liv med Artrose i Danmark (GLA:D®) er et nationalt initiativ fra Forskningsenheden for Muskuloskeletal Funktion og Fysioterapi ved Syddansk Universitet. GLA:D® repræsenter en evidensbaseret behandlingsindsats for patienter med knæ- og hofteartrose bestående af patientuddannelse og neuromuskulær træning og understøtter implementering af de nationale kliniske retningslinjer på området. GLA:D® tilbydes i hele landet. Ved udgangen af 2017 er 1.109 klinikere uddannet i GLA:D® og 383 enheder heraf 34 kommuner har haft patienter i forløb. Næsten 30.000 patienter har i løbet af de sidste 5 år deltaget i et GLA:D® -forløb. I GLA:D® Årsrapport 2017 kan du bl.a. få et overblik over de resultater patienterne har opnået i form af lavere smerte, lavere forbrug af smertestillende medicin, bedre funktion og bedre livskvalitet

Breathing Exercises for Patients with Asthma in Specialist Care:A Multicenter Randomized Clinical Trial

RATIONALE: Moderate to severe asthma is associated with impaired asthma control and quality of life (QoL) despite access to specialist care and modern pharmacotherapy. Breathing exercises (BrEX) improve QoL in incompletely controlled mild asthma, but impact in moderate to severe asthma is unknown. OBJECTIVES: To investigate the effectiveness of BrEX as adjuvant treatment on QoL in patients with uncontrolled moderate to severe asthma. METHODS: Adult patients with incompletely controlled asthma attending respiratory specialist clinics were randomized to usual specialist care (UC) or UC and BrEX (UC + BrEX) with three individual physiotherapist-delivered sessions and home exercises. Primary outcome was asthma-related QoL (Mini-Asthma Quality of Life Questionnaire [Mini-AQLQ]) at 6 months on the basis of intention-to-treat analysis. Secondary outcomes: Mini-AQLQ at 12 months, lung function, 6-minute-walk test, physical activity level, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale, and adverse events. Repeated-measures mixed-effects models were used to analyze data. Poisson regression models were used to analyze adverse event incidence rate ratio. RESULTS: A total of 193 participants were allocated to UC + BrEX (n = 94) or UC (n = 99). UC + BrEX was superior in the primary outcome (adjusted mean change difference, 0.35; 95% confidence interval [CI], 0.07 to 0.62). Superiority in Mini-AQLQ was sustained at 12 months (0.38; 95% CI, 0.12 to 0.65). A minor improvement in Hospital Anxiety and Depression Scale depression score at 6 months favoring UC + BrEX (−0.90; 95% CI, −1.67 to −0.14) was observed. Asthma-related adverse events occurred similarly in UC + BrEX and UC participants: 14.9% versus 18.1% (P = 0.38). CONCLUSIONS: BrEX as add-on to usual care improve asthma-related QoL in incompletely controlled asthma regardless of severity and with no evidence of harm. Clinical trial registered with www.clinicaltrials.gov (NCT 03127059)